Royalty Pharma Raises Offer for Elan to as Much as $12 Per ADR

Royalty Pharma Raises Offer for Elan to as Much as $12 Per ADR

Biogen Inc. via Bloomberg

Elan Corp. also said it will pay shareholders dividends directly linked to Tysabri sales as a 20 percent share of the royalty received from Biogen.